Ahmadieh Hamid, Vafi Nasser
Ophthalmic Research Center, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Tehran, Iran.
Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1731-3. doi: 10.1007/s00417-007-0636-z. Epub 2007 Jul 25.
To report the dramatic response of juxtafoveal choroidal neovascularization (CNV) associated with choroidal osteoma to a single intravitreal injection of bevacizumab.
A 19-year-old female presented with decreased visual acuity and metamorphopsia in her right eye. Best corrected visual acuity assessment, ophthalmic examination, fundus photography, fluorescein angiography, optical coherence tomography (OCT), and high-resolution computed tomography (CT) scan of the orbit was performed. A diagnosis of classic juxtafoveal CNV associated with choroidal osteoma was made. Intravitreal injection of 1.25 mg of bevacizumab was performed.
Visual acuity of the right eye was 20/200 before treatment. Visual improvement to 20/25 and the resolution of metamorphopsia was noticed six weeks after the intravitreal injection of bevacizumab. Regression of the CNV was confirmed according to ophthalmoscopic, fluorescein angiographic, and OCT findings. The treatment effect persisted during a 9-month follow-up period.
The intravitreal injection of bevacizumab can result in the rapid regression of CNV secondary to choroidal osteoma.
报告玻璃体腔内单次注射贝伐单抗对与脉络膜骨瘤相关的黄斑旁脉络膜新生血管（CNV）的显著疗效。
一名19岁女性右眼视力下降并出现视物变形。进行了最佳矫正视力评估、眼科检查、眼底照相、荧光素血管造影、光学相干断层扫描（OCT）以及眼眶高分辨率计算机断层扫描（CT）检查。诊断为与脉络膜骨瘤相关的典型黄斑旁CNV。进行了玻璃体腔内注射1.25 mg贝伐单抗。
治疗前右眼视力为20/200。玻璃体腔内注射贝伐单抗六周后，视力提高到20/25且视物变形消失。根据眼底镜、荧光素血管造影和OCT检查结果证实CNV消退。在9个月的随访期内治疗效果持续存在。
玻璃体腔内注射贝伐单抗可使脉络膜骨瘤继发的CNV迅速消退。
